Search Results - "Pimentel, Franklin F"

Pressor response to chemoreflex activation before and after microinjection of glycine into the NTS of awake rats by Pimentel, Franklin F, Bonagamba, Leni G H, Machado, Benedito H

“…Microinjection of glycine into the rostral (bilateral) and caudal (midline) commissural nucleus of the solitary tract (NTS) using three guide cannulas…”
Get more information

Abstract PS9-27: Estimation of clinical benefit and economic burden for using a commercial 70-gene signature test for Brazilian breast cancer patients in the public health system by Pimentel, Franklin F, Buzatto, Isabela PC, Rodrigues, Tamara CGF, Borba, Jessica MC, Peruchi, Karoline PI, de Andrade, Jurandyr M, Tiezzi, Daniel G

“…Background The clinical benefit of adjuvant chemotherapy (CT) for breast cancer (BC) depends on several factors, like menopausal status, stage and molecular…”
Get full text

Abstract P2-08-31: Role of body mass index in Brazilian breast cancer patients: Clinical-pathological characteristics and outcome in a single-institution retrospective cohort by Orlandini, Leonardo F, Pimentel, Franklin F, Carrara, Hélio HA, dos Reis, Francisco JC, de Andrade, Jurandyr M, Tiezzi, Daniel G

“…Background: Despite of several studies described body mass index (BMI) as a poor prognostic factor in breast cancer (BC) patients, the available data are still…”
Get full text

Abstract P5-05-08: Comparative evaluation of a trastuzumab biosimilar or originator trastuzumab in association with pertuzumab: Binding and biological activities in cell culture-based assays by Pimentel, Franklin F, Toledo, Juliano S, Gonçalves, João, Alves, Leandro L, de Paula, Mayara I, de Andrade, Jurandyr M, Tiezzi, Daniel G, Chammas, Roger

“…Background: trastuzumab (TZB) is approved for the treatment of HER2-positive (HER2+) breast cancer in different indications and schemes. The association of…”
Get full text

Abstract P2-08-22: Adjuvant trastuzumab effectiveness in a cohort of HER2-positive breast cancer Brazilian patients treated in a public hospital: The impact in public health planning compared to clinical trial data by Orlandini, Leonardo F, Pimentel, Franklin F, Carrara, Hélio HA, Reis, Francisco JC dos, de Andrade, Jurandyr M, Tiezzi, Daniel G

“…Background: About 20% of breast cancer (BC) subtypes are classified as HER2-positive (HER2+), recognized as a biomarker for worse prognosis. Trastuzumab (T) is…”
Get full text

Abstract PS13-30: Evaluation of factors related to efficacy and safety of neo/adjuvant chemotherapy for breast cancer as a brief estimate of the impact of COVID-19 pandemic by Pimentel, Franklin F, Borba, Jessica MC, Rodrigues, Tamara CGF, Peruchi, Karoline PI, Carrara, Helio HA, de Andrade, Jurandyr M, Candido dos Reis, Francisco J

“…Background COVID-19 pandemic presented as a challenge to breast cancer (BC) treatment, especially considering safety concerns and resource scarcity. Treatment…”
Get full text

Abstract 1035: WAS/WASL interacting protein family, member 2 (WIPF2) expression in breast carcinomas by Tiezzi, Daniel G., Pimentel, Franklin F., Antonio, Heriton MR, Sicchieri, Renata, Tirapelli, Daniela PC, Oliveira, Fabio M., Marana, Heitor RC, Silva, Alfredo R., Bosland, Maarten C., Andrade, Jurandyr M., Carlotti Jr, Carlos G.

“…ERBB2 over-expression in breast carcinomas is associated with poor prognosis and early metastatic dissemination. The gene WIPF2 is located on the position…”
Get full text